Submitted for Publication: October 29, 2010; final revision received March 15, 2011; accepted March 31, 2011.
Published Online: June 6, 2011. doi:10.1001/archgenpsychiatry.2011.64
Financial Disclosure: Dr Edinger has been a consultant for Kingsdown and Philips/Respironics and has received research support from Philips/Respironics. Dr Wyatt has received research support from Philips/Respironics. Dr Krystal has received grants or research support from the National Institutes of Health, sanofi-aventis, Cephalon, GlaxoSmithKline, Merck, Neurocrine, Pfizer, Sepracor, Somaxon, Takeda, Transcept, Philips/Respironics, Neurogen, Evotec, Astellas, and Neuronetics and has been a consultant for Abbott, Actelion, Arena, Astellas, Axiom, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, GlaxoSmithKline, Jazz, Johnson& Johnson, King, Merck, Neurocrine, Neurogen, Neuronetics, Novartis, Organon, Ortho-McNeil-Janssen, Pfizer, Respironics, Roche, sanofi-aventis, Sepracor, Somaxon, Takeda, Transcept, and Kingsdown.
Funding/Support: This research was supported by grant R01 MH67057 from the National Institute of Mental Health.
Role of the Sponsor: The funding agency had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.
Disclaimer: The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.
Previous Presentation: This paper was presented in part at the 20th Congress of the European Sleep Research Society; September 17, 2010; Lisbon, Portugal.
Additional Contributions: Kevan VanLandingham, MD, PhD, Laurie Keefer, PhD, Andrea Canada, PhD, Aimee Danielson, PhD, Babak Mokhlesi, MD, Margaret Park, MD, Mike Summers, MD, and Tony Proske, MD, served as clinical interviewers and Marci Loiselle, Angela Kirby, Pamela Smith, Faye Knauss, Kathy Schelble, Laura Benson, and Lindsey Gluszek served as study coordinators.